Rocket Pharmaceuticals Secures FDA RMAT Designation for Pioneering Gene Therapy Targeting PKP2-Arrhythmogenic CardiomyopathyIn a significant advancement for both Rocket Pharmaceuticals, Inc. and the realm of genetic therapies, the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company s investigational gene therapy, RP-A601. This promising adeno-associated virus (AAV)-based treatment aims to address the rare and debilitating PKP2-arrhythmogenic cardiomyopathy, a condition characterised by life-threatening arrhythmias and a substantial lack of effective therapies.Rocket Pharmaceuticals, a fully integrated biotechnology company based in Cra...
In an epoch-defining announcement, Rocket Pharmaceuticals, Inc. a leader in the biotechnology industry, has unveiled promising data from its Phase 1 clinical trial of RP-A601, aimed at treating patients with plakophilin2-related arrhythmogenic cardiomyopathy (PKP2-ACM). This revelation, set for a late-breaking oral presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, marks a significant milestone in the journey toward genetic therapy for rare cardiac disorders.At the heart of Rocket Pharmaceuticals’ advancements is its audacious commitment to addressing conditions with high unmet medical needs. The recent Phase 1 trial stands as a testament to this resolve. By focusing ...
: Rocket Pharmaceuticals, Inc. a leading biotechnology company, has announced significant milestones in their genetic therapy programs. The publication of long-term data in the New England Journal of Medicine and a presentation at the Late-Breaking Scientific Sessions of the 2024 American Heart Association Conference have highlighted the promising advancements of their Phase 1 RP-A501 trial. This study explores the safety and efficacy of RP-A501, a novel gene therapy for Danon disease, a rare disorder with high unmet medical need. Danon disease is a multi-system lysosomal storage disorder characterized by cardiomyopathy, skeletal myopathy, and intellectual disability, resulting from mutations in the LAMP2 ...
CRANBURY, N.J. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a prominent player in the biotechnology sector, specializes in the development of innovative gene therapies aimed at treating rare diseases that currently have significant unmet medical needs. In a series of recent announcements, the company has outlined substantial progress concerning its clinical trials, financial performance, and regulatory developments. Completion of Enrollment in Pivotal Phase 2 Trial for RP-A501One of the most notable announcements from Rocket Pharmaceuticals is the completion of patient enrollment in its global pivotal Phase 2 clinical trial evaluating RP-A501, a groundbreaking treatment for Danon disease. Danon disease is...
In its latest quarterly report, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) revealed its financial results for the second quarter of 2024, along with significant updates on its clinical programs focused on genetic therapies for rare disorders. Based in Cranbury, New Jersey, Rocket Pharmaceuticals positions itself as a fully integrated biotechnology company with a focus on developing a sustainable pipeline aimed at addressing high unmet medical needs.For the quarter ending June 30, 2024, Rocket Pharmaceuticals highlighted ongoing advancements in its clinical pipeline, particularly in the development of its RP-A501 and RP-A601 programs. RP-A501 is aimed at treating Danon disease, a rare genetic disorder affect...
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) Following FDA Complete Response Letter Cranbury, N.J. - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company specializing in the development of genetic therapies for rare disorders with high unmet medical needs, has announced a key regulatory update concerning their lead gene therapy product, KRESLADI (marnetegragene autotemcel; marne-cel). KRESLADI is a lentiviral (LV) vector-based gene therapy specifically designed to treat severe leukocyte adhesion deficiency-I (LAD-I).Over the past few years, Rocket Pharmaceuticals has made significant advancements in their mis...
Rocket Pharmaceuticals, a late-stage biotechnology company specializing in genetic therapies for rare disorders, recently presented longer-term data updates from its lentiviral (LV) vector hematology portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The company also announced an update on the FDA review timeline for its treatment KRESLADI (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency-I (LAD-I). Additionally, Rocket Pharmaceuticals reported its financial results for the third quarter of 2023.1. Positive Data from LV Hematology Portfolio:At the ASGCT meeting, Rocket Pharmaceuticals presented positive longer-term data updates from its Phase 1/2...
Rocket Pharmaceuticals, a late-stage biotechnology company dedicated to developing innovative genetic therapies for rare disorders, has recently reported its financial and operational results for the fourth quarter and full year ending December 31, 2023. The company reported strong performance and progress across all six disclosed gene therapy programs, solidifying its position as a leader in the field.Throughout 2023, Rocket Pharmaceuticals has consistently demonstrated its commitment to addressing high unmet medical needs and advancing its pipeline of genetic therapies. The company s achievements in the fourth quarter, as well as updates from the third quarter, highlight notable progress and serve as a tes...
Sources:
Rocket Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Rocket Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Rocket Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
